Cardoso B, Loureiro P, Gomes I, Gordo A, Banazol N, Fragata I, Trigo C, Pinto F, Fragata José
Department of Pediatric Cardiology, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal.
Department of Cardiothoracic Surgery, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal.
World J Pediatr Congenit Heart Surg. 2016 May;7(3):321-8. doi: 10.1177/2150135116637806.
The appropriateness of rheumatic mitral valve repair remains controversial due to the risks of recurrent mitral dysfunction and need for reoperation. The aims of this study were to determine the overall short- and long-term outcomes of pediatric rheumatic mitral valve surgery in our center.
Single-center, observational, retrospective study that analyzed the results of rheumatic mitral valve surgery in young patients, consecutively operated by the same team, between 1999 and 2014.
We included 116 patients (mean age = 12.6 ± 3.5 years), of which 66 (57%) were females. A total of 116 primary surgical interventions and 22 reoperations were performed. Primary valve repair was possible in 86 (74%) patients and valve replacement occurred in 30 (26%). Sixty percent of the patients were followed up beyond three months after surgery (median follow-up time = 9.2 months [minimum = 10 days; maximum = 15 years]). Long-term clinical outcomes were favorable, with most patients in New York Heart Association functional class I (89.6%) and in sinus rhythm (85%). Freedom from reoperation for primary valve repair at six months, five years, and ten years was 96.4% ± 0.25%, 72% ± 0.72%, and 44.7% ± 1.34%, respectively. Freedom from reoperation for primary valve replacement at six months, five years, and ten years was 100%, 91.7% ± 0.86%, and 91.7% ± 0.86%, respectively. Mitral stenosis as the primary lesion dictated early reintervention.
Despite the greater rate of reoperation, especially when the primary lesion was mitral stenosis, rheumatic mitral valve repair provides similar clinical outcomes as compared with replacement, with the advantage of avoiding anticoagulation.
由于存在二尖瓣功能障碍复发风险以及再次手术的必要性,风湿性二尖瓣修复术的适用性仍存在争议。本研究的目的是确定我们中心小儿风湿性二尖瓣手术的总体短期和长期结果。
单中心、观察性、回顾性研究,分析了1999年至2014年间由同一团队连续为年轻患者实施的风湿性二尖瓣手术结果。
我们纳入了116例患者(平均年龄=12.6±3.5岁),其中66例(57%)为女性。共进行了116次初次手术干预和22次再次手术。86例(74%)患者可行初次瓣膜修复,30例(26%)患者进行了瓣膜置换。60%的患者在术后三个月以上进行了随访(中位随访时间=9.2个月[最短=10天;最长=15年])。长期临床结果良好,大多数患者处于纽约心脏协会心功能I级(89.6%)且为窦性心律(85%)。初次瓣膜修复术后六个月、五年和十年的再次手术-free率分别为96.4%±0.25%、72%±0.72%和44.7%±1.34%。初次瓣膜置换术后六个月、五年和十年的再次手术-free率分别为100%、91.7%±0.86%和91.7%±0.86%。以二尖瓣狭窄作为主要病变预示着早期再次干预。
尽管再次手术率较高,尤其是当主要病变为二尖瓣狭窄时,风湿性二尖瓣修复术与置换术相比临床结果相似,具有避免抗凝的优势。